Abstract
Biochemical recurrence after radical prostatectomy (RP) is associated with risk factors including high baseline levels of prostate-specific antigen (PSA), extraprostatic extension, positive surgical margins (R1), and Gleason score ≥8. The 5-year biochemical progression rate for patients with these characteristics has been estimated to be as high as 50–70 %. Two treatment approaches for the postoperative management of these patients are adjuvant radiation therapy in men with an undetectable PSA or observation followed by early salvage radiation therapy (SRT) in men with persisting or rising PSA after initial postoperative undetectable values.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
